ESRRA and breast cancer: Our functional genomic and metabolomic data coupled with expression profiling suggest that these PGC-1α effects are likely mediated through ERRα in breast cancer cells since the re-expression of ERRα in resistant cells provides the optimal metabolic context required to survive the lapatinib-induced oxidative stress insult.